Zogenix (ZGNX) Misses Q4 EPS by 3c

Zogenix (NASDAQ: ZGNX) reported Q4 EPS of ($0.14), $0.03 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $14.9 million versus the consensus estimate of $12.5 million.

2015 Financial Guidance

Zogenix is not providing financial guidance on expected 2015 revenues and expenses at this time. However, the Company expects its current financial resources and the expected proceeds from the sale of the Zohydro ER business to provide a cash runway through three significant clinical milestones: the end of phase 2 meeting for Relday, followed by the regulatory submissions in the U.S. and Europe for ZX008, which are anticipated in the fourth quarter 2016. The Company expects to provide updated financial guidance after the transaction is closed on its first quarter 2015 conference call.

For earnings history and earnings-related data on Zogenix (ZGNX) click here.

You May Also Be Interested In

• Wolverine World Wide (WWW) Tops Q2 EPS by 2c; offers guidance
• SCYNEXIS (SCYX) PT Raised to $33 at Guggenheim
• 22nd Century Group (XXII) Misses Q2 EPS by 9800c